Sugi Predict

Sugi Predict / Compounds / SCHEMBL4177585

SCHEMBL4177585

SCHEMBL4177585

CNS(=O)(=O)c1ccccc1I

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.43
▸ NR3C2 P08235 1/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ ITGAV P06756 1/20 0.41
▸ TSHR P16473 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ ALOX5AP P20292 1/20 0.38
▸ FEN1 P39748 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA3 P07451 1/20 0.38
▸ CA4 P22748 1/20 0.38
▸ CA6 P23280 1/20 0.38
▸ CA5A P35218 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4731653 0.84 CYP1A2 (0.55) CYP1A2ALDH1A1NR3C2L3MBTL1LMNA
SCHEMBL29321430 0.82 ITGAV (0.43) ALDH1A1L3MBTL1ITGAVTSHRGAA
SCHEMBL2893576 0.79 NSD2 (0.50) ALDH1A1LMNAITGAVSMN1; SMN2ALOX5AP
SCHEMBL10892681 0.78 ITGAV (0.41) ITGAVGAACA12CA1CA2
SCHEMBL1767944 0.78 CA1 (0.55) ITGAVCA1CA2HTR1AHTR7
SCHEMBL12561644 0.78 ITGAV (0.48) CYP1A2ALDH1A1LMNAITGAVSMN1; SMN2
SCHEMBL634340 0.76 LMNA (0.57) CYP1A2ALDH1A1NR3C2L3MBTL1LMNA
SCHEMBL30338563 0.76 LMNA (0.57) CYP1A2ALDH1A1NR3C2L3MBTL1LMNA
SCHEMBL10153791 0.76 CYP1A2 (0.49) CYP1A2ALDH1A1NR3C2L3MBTL1LMNA
SCHEMBL3768663 0.75 KEAP1 (0.55) ALDH1A1TSHRCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3480187-B1 METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES UNIV NAT TAIWAN NORMAL (TW) 2023-10-04 — — EP disclosed
EP-3480187-B1 METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES UNIV NAT TAIWAN NORMAL (TW) 2023-10-04 — — EP disclosed
EP-3429994-B1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LTD (GB) 2021-06-16 — — EP disclosed
CN-109748870-B Process for preparing indenoisoquinoline derivatives 姚清发 2021-02-12 — — CN disclosed
US-10336704-B2 Method for preparing indenoisoquinoline derivatives NATIONAL TAIWAN NORMAL UNIVERSITY (TW) 2019-07-02 — — US disclosed
US-10336704-B2 Method for preparing indenoisoquinoline derivatives NATIONAL TAIWAN NORMAL UNIVERSITY (TW) 2019-07-02 — — US disclosed
EP-3480187-A1 METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES National Taiwan Normal University (TW) 2019-05-08 — — EP disclosed
EP-3480187-A1 METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES National Taiwan Normal University (TW) 2019-05-08 — — EP disclosed
US-20190127330-A1 Method for Preparing Indenoisoquinoline Derivatives NATIONAL TAIWAN NORMAL UNIVERSITY (TW) 2019-05-02 — — US disclosed
US-20190127330-A1 Method for Preparing Indenoisoquinoline Derivatives NATIONAL TAIWAN NORMAL UNIVERSITY (TW) 2019-05-02 — — US disclosed
WO-2017158388-A1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LIMITED (GB) 2017-09-21 — — WO disclosed
US-20090197836-A1 Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes VAN POELJE PAUL D 2009-08-06 — — US disclosed
US-7371739-B2 Aryl fructose-1,6-bisphosphatase inhibitors METABASIS THERAPEUTICS, INC. (US) 2008-05-13 — — US disclosed
EP-1265907-B9 NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS METABASIS THERAPEUTICS INC (US) 2007-05-09 — — EP disclosed
EP-1265907-B1 NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS METABASIS THERAPEUTICS INC (US) 2007-01-03 — — EP disclosed
EP-1607401-A1 Novel aryl fructose-1,6-Bisphosphatase inhibitors Metabasis Therapeutics, Inc. (US) 2005-12-21 — — EP disclosed
US-20050176684-A1 Novel aryl fructose-1,6-bisphosphatase inhibitors BOOKSER BRETT C (US) 2005-08-11 — — US disclosed
US-6919322-B2 Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors METABASIS THERAPEUTICS, INC. (US) 2005-07-19 — — US disclosed
US-20020040014-A1 Novel aryl fructose-1,6-Bisphosphatase inhibitors METABASIS THERAPEUTICS, INC. 2002-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197836-A1 Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes FBP1, ALDOA, G6PC1 CYP1A2 3970/4885ALDH1A1 2627/4885NR3C2 4025/4885
US-20020040014-A1 Novel aryl fructose-1,6-Bisphosphatase inhibitors FBP1, SLC5A1, G6PC1 CYP1A2 720/4885ALDH1A1 228/4885NR3C2 2874/4885
US-20050176684-A1 Novel aryl fructose-1,6-bisphosphatase inhibitors FBP1, G6PC1, SLC5A1 CYP1A2 878/4885ALDH1A1 341/4885NR3C2 3209/4885
US-10336704-B2 Method for preparing indenoisoquinoline derivatives CYP1A2, RECQL, RDX CYP1A2 1/4885ALDH1A1 1114/4885NR3C2 1213/4885
US-20190127330-A1 Method for Preparing Indenoisoquinoline Derivatives CYP1A2, RECQL, RDX CYP1A2 1/4885ALDH1A1 1114/4885NR3C2 1213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.